Afficher le profil
Base
| Nom | Pascal LOYER |
| Grade | |
| Equipe | |
| Adresse | CHU Pontchaillou – 2 rue Henri Le Guilloux – 35033 Rennes Cedex |
| Téléphone | |
| Skills | In the field of hepatology: liver physiopathology, liver regeneration, in vitro liver cell models, drug metabolism enzymes, cyclin dependent protein kinases regulating cell cycle and RNA synthesis. In the field of biotechnology: Co-founder of the SynNanoVect (Biogenouest, IBiSA 2015, ISO9001:V2015) platform dedicated to nucleic acid and drug delivery (http://www.synanovect.ueb.eu) I act as reviewer for a number of international scientific journals in the field of hepatology, cell cycle and biotechnologies. Within the INSERM Laboratory U1241, I was leader or partner of several national grants and involved in 1 completed European FP6 project (Liv-ES) and my work is currently funded by INSERM, Ligue contre le Cancer, Fondation pour la Recherche Médicale and Cancéropôle Grand-Ouest. I was the mentor of 6 completed and 2 ongoing doctoral theses from the University of Rennes. I also give nearly 30 hours of lectures per year in the field of cell biology and biotechnologies at the Universities of Rennes, Paris V and Bretagne Sud-Vannes. |
| Research topics and scientific objectives | ResearchGate : https://www.researchgate.net/profile/Pascal_Loyer ORCID : 0000-0002-5656-2673 My research interests are situated in the field of liver metabolisms and the production of innovative copolymer nanoparticles for liver-targeted drug delivery. In order to improve efficacy and tolerance of liver cancers therapies, we pursue the development of innovative peptide-chelator conjugates and radioactive metal-based micropheres/lipiodol and investigate how genetic and acquired factors modulate the efficacy and tolerance of treatments using metals. This work is performed using both in vivo models of liver regeneration and in vitro cultures of rodent and human hepatocytes. |
| Education and main positions held | 2007 Habilitation à Diriger les Recherches, Cellular and Molecular Biology, University of Rennes 1, France 1993 Ph. D. in Cellular and Molecular Biology, University of Rennes 1, France
2017- Team leader, Inserm U1241- Nutrition Metabolisms & Cancer, Pontchaillou Hospital, Rennes, France 2005-16 Senior researcher, Inserm UMR991-Liver-Metabolisms-Cancer, Pontchaillou Hospital, Rennes, France. 2002-05 Sabbatical Years, Visiting scientist, Laboratory of Drs. V. Kidd et J Lahti, Dept. of Tumor Cell Biology, St Jude Children’s Research Hospital, Memphis TN, USA 2000-02 Senior researcher Inserm U522, Liver Research Unit, Pontchaillou Hospital, 35033 Rennes, France 1996-00 Junior researcher Inserm U49, Liver Research Unit, Pontchaillou Hospital, 35033 Rennes, France 1994-96 Post-doctoral training, Laboratory of Drs. V. Kidd et J Lahti, Dept. of Tumor Cell Biology, St Jude Children’s Research Hospital, Memphis TN, USA |
| Current projects | Our main objective is to functionalize with peptides poly(benzyl malate)-based NPs embedding metals such as diaminocarbene-metal complexes (collaboration with Team EXPRES and ENSCR) and to produce new peptides/chelators (TE1PA, tridentate N2O ligand and HYNIC) conjugates complexed to metal radionuclides (64/67Cu, 90Y, 188Re) for diagnosis and treatment of hepatocellular carcinomas (HCC). Following up with our ongoing collaboration with microbiologists of the team METHER, we also produce bacterial magnetosomes, Fe3O4 nanocrystals embedded in phospholipid bilayer and bacterial proteins, which will be genetically modified to express targeting peptides at the surface of magnetosomes, which offer a new strategy for tumor imaging and drug/metal delivery into tumor cells. The NPs, peptides/chelators conjugates and magnetosomes cell uptake and toxicities are studied in vitro in cells accumulating nanovectors such as endothelial cells, hepatocytes and macrophages. Their biodistribution in vivo in normal mice is invetsiagted prior evaluation of drug delivery (metals, antibiotics, chemotherapies, etc.) to target HCC in animal models. |
| Selected publications | [1] Palard X, Edeline J, Rolland Y, Le Sourd S, Pracht M, Laffont S, Lenoir S, Boudjema K, Ugen T, Brun V, Mesbah H, Haumont LA, Loyer P, Garin E. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging, 2018, 45, 392-401. [2] Quesnot N, Bucher S, Gade C, Vlach M, Vene E, Valença S, Gicquel T, Holst H, Robin MA, Loyer P. Production of chlorzoxazone glucuronides via cytochrome P4502E1 dependent and independent pathways in human hepatocytes. Arch Toxicol. 2018 Oct;92(10):3077-3091. [3] Casajus H, Saba S, Vlach M, Vène E, Ribault C, Tranchimand S, Nugier-Chauvin C, Dubreucq E, Loyer P*, Cammas-Marion S*, Lepareur N*. Cell Uptake and Biocompatibility of Nanoparticles Prepared from Poly(benzyl malate) (Co)polymers Obtained through Chemical and Enzymatic Polymerization in Human HepaRG Cells and Primary Macrophages. Polymers, 2018, 10(11), 1244. * co-corresponding authors. [4] Vlach M, Quesnot N, Dubois-Pot-Schneider H, Ribault C, Verres Y, Petitjean K, Rauch C, Morel F, Robin MA, Corlu A, Loyer P. Cytochrome P450 1A1/2, 2B6 and 3A4 HepaRG Cell-Based Biosensors to Monitor Hepatocyte Differentiation, Drug Metabolism and Toxicity. Sensors (Basel). 2019 May 15;19(10):2245 [5] Loyer P, Trembley JH. Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expression. Semin Cell Dev Biol. 2020 Nov;107:36-45. |